Fig. 3. Activity of HCT-13 in a panel of cancer cell lines and non-transformed cells. IC50 values in a panel of human and mouse prostate cancer (PC), small cell lung carcinoma (SCLC), pancreatic ductal adenocarcinoma (PDAC), leukemia, and non-transformed epithelial models treated with HCT-13 + Cu(ii) (20 μM) for 72 h measured by CellTiterGlo.
